RedHill Biopharma (RDHL) Net Cash Flow (2012 - 2023)

RedHill Biopharma (RDHL) has reported Net Cash Flow for 12 consecutive years, with -$10.6 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Net Cash Flow fell 479.42% year-over-year to -$10.6 million in Q2 2023; TTM through Jun 2023 was -$20.0 million, a 19.46% increase from a year earlier, with the FY2025 full-year figure at -$638000.0, up 33.61% from the prior year.
• Net Cash Flow was -$10.6 million for Q2 2023 at RedHill Biopharma, down from -$2.4 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $52.5 million in Q1 2020 and troughed at -$59.4 million in Q2 2020.
• A 5-year average of -$1.2 million and a median of -$1.2 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 973.31% in 2020 and sank 821.02% in 2021, its largest moves.
• Over 5 years, Net Cash Flow stood at $17.3 million in 2019, then plunged by 82.19% to $3.1 million in 2020, then soared by 101.1% to $6.2 million in 2021, then slipped by 23.03% to $4.8 million in 2022, then slumped by 321.46% to -$10.6 million in 2023.
• The last three Net Cash Flow figures came in at -$10.6 million (Q2 2023), -$2.4 million (Q1 2023), and $4.8 million (Q4 2022), per Business Quant data.